when did glp 1 come out The GLP-1 journey: from discovery science to therapeutic impact The Evolution of GLP-1 Users

101 Monserrat-MesquidaM.Quetglas-LlabrsM.CapX.BouzasC.MateosD.PonsA.et al (2020)

MASLD is particularly prevalent among individuals with metabolic dysfunction, with a reported prevalence of up to 68% among patients with type 2 diabetes mellitus (T2DM), while obese individuals have more than a threefold elevated risk of developing this condition [3, 4]

(2017) The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility, Nat

Although numerous studies support an association between gut microbiota dysbiosis and ASD, the reproducibility of these findings across different cohorts remains limitedparticularly in alpha and beta diversity analyses, which frequently yield contradictory results